2017
History of Comorbidities and Survival of Ovarian Cancer Patients, Results from the Ovarian Cancer Association Consortium
Minlikeeva AN, Consortium JL, Freudenheim KH, Eng RA, Cannioto G, Friel JB, Szender B, Segal K, Odunsi P, Mayor B, Diergaarde E, Zsiros LE, Kelemen M, Köbel H, Steed A, deFazio SJ, Group PA, Jordan MW, Fasching HA, Beckmann MA, Risch JA, Rossing J, Doherty MT, Chang-Claude T, Goodman R, Dörk F, Edwards RB, Modugno K, Ness M, Matsuo BY, Mizuno EL, Karlan SK, Goode E, Kjær JM, Høgdall KL, Schildkraut DW, Terry EV, Cramer LE, Bandera LA, Paddock LFAG, Kiemeney R, Massuger H, Sutphen A, Anton-Culver U, Ziogas SA, Menon SJ, Gayther A, Ramus CL, Gentry-Maharaj AH, Pearce J, Wu A, Kupryjanczyk PM, Jensen KB, Webb P, Moysich K. History of Comorbidities and Survival of Ovarian Cancer Patients, Results from the Ovarian Cancer Association Consortium. Cancer Epidemiology Biomarkers & Prevention 2017, 26: 1470-1473. PMID: 28864456, PMCID: PMC5649363, DOI: 10.1158/1055-9965.epi-17-0367.Peer-Reviewed Original ResearchConceptsProgression-free survivalHistory of endometriosisStage of diseaseOvarian cancer patientsOvarian cancer outcomeCancer outcomesCancer patientsCox proportional hazards regression modelProportional hazards regression modelsHazards regression modelsInvasive ovarian carcinomasOvarian cancer prognosisOvarian Cancer Association ConsortiumPooled HRsConcurrent comorbiditiesHistologic subtypeOvarian carcinomaChronic diseasesOvarian cancerWeight statusNeurologic diseaseCancer prognosisComorbiditiesTreatment efficacyNeurological diseases
2006
Population BRCA1 and BRCA2 Mutation Frequencies and Cancer Penetrances: A Kin–Cohort Study in Ontario, Canada
Risch HA, McLaughlin JR, Cole DE, Rosen B, Bradley L, Fan I, Tang J, Li S, Zhang S, Shaw PA, Narod SA. Population BRCA1 and BRCA2 Mutation Frequencies and Cancer Penetrances: A Kin–Cohort Study in Ontario, Canada. Journal Of The National Cancer Institute 2006, 98: 1694-1706. PMID: 17148771, DOI: 10.1093/jnci/djj465.Peer-Reviewed Original ResearchConceptsIncident ovarian cancerAge 80 yearsGeneral Ontario populationOvarian cancerBRCA2 mutationsTypes of cancerMutation carriageCumulative incidenceRelative riskBreast cancerHigh riskGeneral populationBRCA1 mutationsInvasive ovarian cancerCancer incidence ratesFirst-degree relativesBRCA2 mutation frequencyOntario populationUnselected patientsMale breastTestis cancerCancer outcomesPancreatic cancerIncidence rateCancer risk